Protalix banks $25mn from Pfizer
This article was originally published in Scrip
Executive Summary
The 1 May OK from the US FDA of Elelyso (taliglucerase alfa), an enzyme replacement therapy (ERT) for Gaucher disease, bagged Protalix BioTherapeutics a $25 million payment this month, the Israeli drug maker said on 11 June.